Combination of | |
---|---|
Lamivudine | Reverse-transcriptase inhibitor |
Raltegravir | Integrase inhibitor |
Clinical data | |
Trade names | Dutrebis |
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
KEGG |
Lamivudine/raltegravir, sold under the brand name Dutrebis, is a fixed-dose combination antiretroviral medication used in the treatment of HIV/AIDS. [1] It contains lamivudine and raltegravir. It is taken by mouth. [1] Side effects may include lactic acidosis, pancreatitis, liver failure, and severe skin rashes. [1] It was approved for medical use in the United States in 2015. [1] [2]
Lamivudine/raltegravir is not available in the United States. [3]